Pfizer's tafamidis is expected to maintain the lion’s share of the ATTR-CM market even if Alnylam’s HELIOS-B trial were to be positive, two KOLs said.
Chugai Pharmaceutical Co., Ltd. announced that it concluded a license agreement with Roche for zilebesiran, an investigational RNAi therapeutic for hypertension created by Alnylam Pharmaceuticals, Inc. and currently under development by Roche and Alnylam.
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign
Alnylam takes a family road trip to talk about health history
Roche, Alnylam say blood pressure drug succeeds in mid-stage trial